Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).
Clinical trial NCT03728634 · COMPLETED
Trial details
- NCT number
- NCT03728634
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-21
- Primary completion
- 2020-02-20
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.